<p>OncoCyte（纳斯达克代码：OCX - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.26），据 Zacks 报道。OncoCyte 的股本回报率为负 269.32%，净利润率为负 6,122.29%。</p>
<h2>OncoCyte 股价下跌 2.1%</h2>
<p>在周一的午盘交易中，纳斯达克代码：OCX 下跌了$0.06，报$2.81。该股票交易了 64,472 股，较其平均交易量 57,484 股有所增加。该公司的 50 日移动平均价格为$3.17，200 日移动平均价格为$2.70。公司的市值为 8036 万美元，市盈率为-0.64，贝塔值为 0.95。OncoCyte 的 12 个月低点为$1.92，12 个月高点为$4.75。</p>
<h2>分析师评级调整</h2>
<p>几位股票分析师最近对 OCX 股票发表了看法。StockNews.com 在 4 月 6 日（星期日）的一份研究报告中开始覆盖 OncoCyte 的股票，并给予该公司 “卖出” 评级。Lake Street Capital 在 3 月 28 日（星期五）的一份研究报告中开始覆盖 OncoCyte 的股票，并给予 “买入” 评级，目标价为$5.00。Stephens 在 3 月 25 日（星期二）的一份研究报告中重申了 “持平” 评级，并将 OncoCyte 的目标价设定为$4.00。最后，Needham &amp; Company LLC 在 4 月 8 日（星期二）的一份研究报告中重申了 “买入” 评级，并将 OncoCyte 的目标价设定为$4.25。</p>
<p><strong>查看我们最新的 OncoCyte 股票分析</strong></p>
<h2>OncoCyte 公司简介</h2>
<p>（获取免费报告）</p>
<p>OncoCyte Corporation 是一家精准诊断公司，专注于在美国和国际上开发和商业化专有检测。该公司正在开发 DetermaIO，一种基因表达检测，用于评估肿瘤微环境以预测对免疫疗法的反应；DetermaCNI，一种基于血液的监测工具，用于监测癌症患者的治疗效果；以及 VitaGraft，一种基于血液的固体器官移植监测测试。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 OncoCyte 更好</li>
<li>什么是财报？</li>
<li>Palantir 的最新交易可能会冻结其股价</li>
<li>3 只家居改善股票可以升级您的投资组合</li>
<li>4 只汽车制造商股票对关税的反应：赢家和输家</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>这就是为什么看涨期权交易者喜欢 Dutch Bros 股票的原因</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 OncoCyte 吗？</h2>
<p>在考虑 OncoCyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 OncoCyte 并不在名单上。</p>
<p>虽然 OncoCyte 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMDX

<p>OncoCyte（纳斯达克代码：OCX）报告的季度收益为每股亏损 0.26 美元，净利润率为负 6,122.29%，股本回报率为负 269.32%。该股下跌 2.1%，报 2.81 美元，市值为 8036 万美元。分析师的评级不一，StockNews.com 给予 “卖出” 评级，而 Lake Street Capital 则设定了 “买入” 评级，目标价为 5.00 美元。OncoCyte 专注于精准诊断，正在开发几种用于癌症治疗监测的专有检测</p>

<p>OncoCyte (NASDAQ:OCX - Get Free Report) posted its earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, Zacks reports. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%.</p>
<div class="lb-trans"><p>OncoCyte（纳斯达克代码：OCX - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.26），据 Zacks 报道。OncoCyte 的股本回报率为负 269.32%，净利润率为负 6,122.29%。</p>
</div><h2>OncoCyte Stock Down 2.1%</h2>
<div class="lb-trans"><h2>OncoCyte 股价下跌 2.1%</h2>
</div><p>NASDAQ:OCX traded down $0.06 during mid-day trading on Monday, hitting $2.81. 64,472 shares of the stock traded hands, compared to its average volume of 57,484. The business's 50-day moving average price is $3.17 and its 200 day moving average price is $2.70. The company has a market cap of $80.36 million, a PE ratio of -0.64 and a beta of 0.95. OncoCyte has a 12-month low of $1.92 and a 12-month high of $4.75.</p>
<div class="lb-trans"><p>在周一的午盘交易中，纳斯达克代码：OCX 下跌了$0.06，报$2.81。该股票交易了 64,472 股，较其平均交易量 57,484 股有所增加。该公司的 50 日移动平均价格为$3.17，200 日移动平均价格为$2.70。公司的市值为 8036 万美元，市盈率为-0.64，贝塔值为 0.95。OncoCyte 的 12 个月低点为$1.92，12 个月高点为$4.75。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities analysts have recently weighed in on OCX shares. StockNews.com started coverage on shares of OncoCyte in a research note on Sunday, April 6th. They issued a &#34;sell&#34; rating for the company. Lake Street Capital began coverage on shares of OncoCyte in a research note on Friday, March 28th. They set a &#34;buy&#34; rating and a $5.00 price objective for the company. Stephens reaffirmed an &#34;equal weight&#34; rating and set a $4.00 price objective on shares of OncoCyte in a research note on Tuesday, March 25th. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday, April 8th.</p>
<div class="lb-trans"><p>几位股票分析师最近对 OCX 股票发表了看法。StockNews.com 在 4 月 6 日（星期日）的一份研究报告中开始覆盖 OncoCyte 的股票，并给予该公司 “卖出” 评级。Lake Street Capital 在 3 月 28 日（星期五）的一份研究报告中开始覆盖 OncoCyte 的股票，并给予 “买入” 评级，目标价为$5.00。Stephens 在 3 月 25 日（星期二）的一份研究报告中重申了 “持平” 评级，并将 OncoCyte 的目标价设定为$4.00。最后，Needham &amp; Company LLC 在 4 月 8 日（星期二）的一份研究报告中重申了 “买入” 评级，并将 OncoCyte 的目标价设定为$4.25。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on OncoCyte</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 OncoCyte 股票分析</strong></p>
</div><h2>OncoCyte Company Profile</h2>
<div class="lb-trans"><h2>OncoCyte 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.</p>
<div class="lb-trans"><p>OncoCyte Corporation 是一家精准诊断公司，专注于在美国和国际上开发和商业化专有检测。该公司正在开发 DetermaIO，一种基因表达检测，用于评估肿瘤微环境以预测对免疫疗法的反应；DetermaCNI，一种基于血液的监测工具，用于监测癌症患者的治疗效果；以及 VitaGraft，一种基于血液的固体器官移植监测测试。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than OncoCyte</li>
<li>What Are Earnings Reports?</li>
<li>Palantir’s Latest Deal Could Put a Freeze on Its Stock Price</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>4 Automaker Stocks React to Tariffs: Winners and Losers</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Here's Why Call Option Traders Love Dutch Bros Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 OncoCyte 更好</li>
<li>什么是财报？</li>
<li>Palantir 的最新交易可能会冻结其股价</li>
<li>3 只家居改善股票可以升级您的投资组合</li>
<li>4 只汽车制造商股票对关税的反应：赢家和输家</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>这就是为什么看涨期权交易者喜欢 Dutch Bros 股票的原因</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0NY" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OCX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in OncoCyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 OncoCyte 吗？</h2>
</div><p>Before you consider OncoCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 OncoCyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OncoCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 OncoCyte 并不在名单上。</p>
</div><p>While OncoCyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 OncoCyte 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

OncoCyte（NASDAQ:OCX）公布季度财务业绩